Article
Treatment of Chronic Spontaneous Urticaria With Benralizumab: Report of Primary Endpoint Completer Analysis, Secondary and Exploratory Endpoints
2020-10-09
Abstract excerpt
<h4>Background: </h4> Standard of care for chronic spontaneous urticaria (CSU) includes second-generation H1-antihistamines (SGAH) but is often ineffective even with four-times the FDA-recommended dose. Urticarial lesions are commonly characterized by increased lymphocytes with perivascular eosinophilic infiltrates implying a role for the interleukin-5 (IL5). Objective. This study investigated the effects of benra...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f7212eb3-b68a-578d-b6cd-ee5133902d50
- DOI
- 10.22541/au.160226445.57744780/v1
